These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32204943)

  • 61. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru.
    Lanata CF; Andrade T; Gil AI; Terrones C; Valladolid O; Zambrano B; Saville M; Crevat D
    Vaccine; 2012 Sep; 30(41):5935-41. PubMed ID: 22863660
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA.
    Dayan GH; Thakur M; Boaz M; Johnson C
    Vaccine; 2013 Oct; 31(44):5047-54. PubMed ID: 24021313
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease.
    Pasin C; Halloran ME; Gilbert PB; Langevin E; Ochiai RL; Pitisuttithum P; Capeding MR; Carrasquilla G; Frago C; Cortés M; Chambonneau L; Moodie Z
    PLoS One; 2018; 13(12):e0207878. PubMed ID: 30543657
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A recombinant live attenuated tetravalent vaccine for the prevention of dengue.
    Guy B; Noriega F; Ochiai RL; L'azou M; Delore V; Skipetrova A; Verdier F; Coudeville L; Savarino S; Jackson N
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28590795
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.
    Sabchareon A; Wallace D; Sirivichayakul C; Limkittikul K; Chanthavanich P; Suvannadabba S; Jiwariyavej V; Dulyachai W; Pengsaa K; Wartel TA; Moureau A; Saville M; Bouckenooghe A; Viviani S; Tornieporth NG; Lang J
    Lancet; 2012 Nov; 380(9853):1559-67. PubMed ID: 22975340
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Quadrivalent Human Papillomavirus Vaccine in Boys and Girls 9-13 Years of Age in Malaysia: A Phase IIIb, Randomized, Open-label Study.
    Hassan J; Toh TH; Sivapunniam SK; Hasim R; Ghazali NF; Sulaiman S; Koh MT; Meyer S; Toh ML; Zocchetti C; Vigne C; Mascareñas C
    Pediatr Infect Dis J; 2021 Aug; 40(8):774-781. PubMed ID: 34250977
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Biodistribution and safety of a live attenuated tetravalent dengue vaccine in the cynomolgus monkey.
    Ravel G; Mantel N; Silvano J; Rogue A; Guy B; Jackson N; Burdin N
    Vaccine; 2017 Oct; 35(43):5918-5923. PubMed ID: 28882438
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents.
    Biswal S; Reynales H; Saez-Llorens X; Lopez P; Borja-Tabora C; Kosalaraksa P; Sirivichayakul C; Watanaveeradej V; Rivera L; Espinoza F; Fernando L; Dietze R; Luz K; Venâncio da Cunha R; Jimeno J; López-Medina E; Borkowski A; Brose M; Rauscher M; LeFevre I; Bizjajeva S; Bravo L; Wallace D;
    N Engl J Med; 2019 Nov; 381(21):2009-2019. PubMed ID: 31693803
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Performance Evaluation of a Dengue IgG Rapid Diagnostic Test Designed to Determine Dengue Serostatus as Part of Prevaccination Screening.
    Liberal V; Forrat R; Zhang C; Pan C; Bonaparte M; Yin W; Zheng L; Viscardi V; Wu Y; Ataman-Önal Y; Savarino S; Chen C
    Microbiol Spectr; 2022 Jun; 10(3):e0071121. PubMed ID: 35604130
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Optimal dengue vaccination strategies of seropositive individuals.
    Shim E
    Math Biosci Eng; 2019 Feb; 16(3):1171-1189. PubMed ID: 30947414
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine.
    Wilder-Smith A; Massad E
    Expert Rev Vaccines; 2016; 15(4):437-41. PubMed ID: 26775653
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge.
    Halstead SB
    Am J Trop Med Hyg; 2016 Oct; 95(4):741-745. PubMed ID: 27352870
    [TBL] [Abstract][Full Text] [Related]  

  • 73. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
    Guy B; Barrere B; Malinowski C; Saville M; Teyssou R; Lang J
    Vaccine; 2011 Sep; 29(42):7229-41. PubMed ID: 21745521
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The Immunogenicity and Safety of CYD-Tetravalent Dengue Vaccine (CYD-TDV) in Children and Adolescents: A Systematic Review.
    Agarwal R; Wahid MH; Yausep OE; Angel SH; Lokeswara AW
    Acta Med Indones; 2017 Jan; 49(1):24-33. PubMed ID: 28450651
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection.
    Guy B; Jackson N
    Nat Rev Microbiol; 2016 Jan; 14(1):45-54. PubMed ID: 26639777
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity.
    Poo J; Galan F; Forrat R; Zambrano B; Lang J; Dayan G
    Pediatr Infect Dis J; 2011 Jan; 30(1):e9-17. PubMed ID: 21042231
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Dengue vaccine development: status and future.
    Wilder-Smith A
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 Jan; 63(1):40-44. PubMed ID: 31784763
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Implementation strategies for the first licensed dengue vaccine: A meeting report.
    Fongwen N; Delrieu I; Ham LH; Gubler DJ; Durbin A; Ooi EE; Peeling RW; Flasche S; Hartigan-Go K; Clifford S; Martinez CT; de Lamballerie X; Barnighausen T; Wilder-Smith A
    Vaccine; 2021 Aug; 39(34):4759-4765. PubMed ID: 34253416
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy.
    Rabaa MA; Girerd-Chambaz Y; Duong Thi Hue K; Vu Tuan T; Wills B; Bonaparte M; van der Vliet D; Langevin E; Cortes M; Zambrano B; Dunod C; Wartel-Tram A; Jackson N; Simmons CP
    Elife; 2017 Sep; 6():. PubMed ID: 28871961
    [TBL] [Abstract][Full Text] [Related]  

  • 80. First Experience of Concomitant Vaccination Against Dengue and MMR in Toddlers.
    Crevat D; Brion JD; Gailhardou S; Laot TM; Capeding MR
    Pediatr Infect Dis J; 2015 Aug; 34(8):884-92. PubMed ID: 25966916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.